Search Results for "Mylan Atovaquone And Proguanil 250mg 100mg Tablet"

00:43 EDT 28th July 2016 | BioPortfolio

Matching Channels

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

Resistance to antimalarial atovaquone does not spread

Atovaquone could be used more widely to treat malaria since resistance does not spread to subsequent generations of the malaria parasite.

Australian researchers confirm Atovaquone's ability to combat malaria parasite

Researchers at the University of Melbourne, Australia, have discovered that an anti-malarial drug called Atovaquone, which was thought to be ineffective, has the ability to combat the malaria parasite...

Mutant malaria parasites resistant to antimalarial Atovaquone cannot spread: new research

By Prodita Sabarini, The Conversation Resistance to a commonly used antimalarial medication, Atovaquone, can’t spread to the general human population, new research suggests. This is significant as s...

Old Malaria Drug May Have New Role Fighting Cancer

An off-patent antimalarial, atovaquone, has been used to enhance the cancer-killing abilities of radiation. Atovaquone came to be evaluated as a radiotherapy adjunct after it emerged as a standout p...

Mylan To Buy Meda In $9.9 Bln Deal; Expects Significant Accretion To Earnings

CANONSBURG (dpa-AFX) - Mylan N.V. (MYL) announced a recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to Mylan. The total offer consideration consi...

Mylan announces $9.9 billion Meda acquisition

David SalazarSpecialty pharmaceutical company Meda is being acquired by Mylan, expanding Mylan's reach into emerging markets, building on its recent specialty and branded generics acquisitions and...

Mylan to buy Swedish drugmaker Meda in $7.2 billion deal

Generic drugmaker Mylan NV said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company. The move comes three months after Mylan gave up on its s...

Is this Large Market Cap Stock target price reasonable for Mylan N.V. (NASDAQ:MYL)?

The company in question is, Mylan N.V. currently with a stock price of 46.6 . The market cap for Mylan N.V. is 23785.2, and is in the sector Healthcare, and Drugs - Generic industry.

Matching PubMed Articles

Exploration of the associations of touch-screen tablet computer usage and musculoskeletal discomfort.

Tablet users may be at high risk of developing physical discomfort because of their usage behaviors and tablet design.

Switching from a two-tablet regimen of tenofovir/emtricitabine and efavirenz to a one-tablet regimen may affect patients' perceptions and drug management.

Simplification of antiretroviral therapy enhances a patient's adherence but a new formulation could also lead to new adverse events and changes in daily routine. This study compared medication adheren...

Microstructure of Tablet-Pharmaceutical Significance, Assessment, and Engineering.

To summarize the microstructure - property relationship of pharmaceutical tablets and approaches to improve tablet properties through tablet microstructure engineering.

Tablet Apps and Dexterity: Comparison Between 3 Age Groups and Proof of Concept for Stroke Rehabilitation.

Touch screen tablet technology might be suitable for self-training of impaired dexterity poststroke. We compared performance of app-based hand activities in individuals without a disability from 3-age...


Different solvents (hexane, chloroform, ethyl acetate, butanol and water, respectively) were used to identify the effect of PL fractions (PLFs) on ruminal biohydrogenation (BH) and ruminal methanogene...

Search Whole site using Google

Quick Search
Advertisement Advertisement